Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||
| DOI | 10.1016/J.JALZ.2017.08.013 | ||
| Año | 2018 | ||
| Tipo |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Objective To determine whether the extent of overlap of the genetic architecture among the sporadic late-onset Alzheimer's Disease (sLOAD), familial late-onset AD (fLOAD), sporadic early-onset AD (sEOAD), and autosomal dominant early-onset AD (eADAD). Methods Polygenic risk scores (PRSs) were constructed using previously identified 21 genome-wide significant loci for LOAD risk. Results We found that there is an overlap in the genetic architecture among sEOAD, fLOAD, and sLOAD. The highest association of the PRS and risk (odds ratio [OR] = 2.27; P = 1.29 × 10−7) was observed in sEOAD, followed by fLOAD (OR = 1.75; P = 1.12 × 10−7) and sLOAD (OR = 1.40; P = 1.21 × 10−3). The PRS was associated with cerebrospinal fluid ptau181-Aβ42 on eADAD (P = 4.36 × 10−2). Conclusion Our analysis confirms that the genetic factors identified for LOAD modulate risk in sLOAD and fLOAD and also sEOAD cohorts. Specifically, our results suggest that the burden of these risk variants is associated with familial clustering and earlier onset of AD. Although these variants are not associated with risk in the eADAD, they may be modulating age at onset.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Cruchaga, Carlos | Hombre |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| 2 | Del-Aguila, Jorge L. | Hombre |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| 3 | Saef, Benjamin | Hombre |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| 4 | Black, Kathleen | Mujer |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| 5 | Fernandez, Maria Victoria | Mujer |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| 6 | Budde, John | Hombre |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| 7 | Ibanez, Laura | Mujer |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| 8 | Deming, Yuetiva | - |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| 9 | Kapoor, Manav | - |
Icahn School of Medicine at Mount Sinai - Estados Unidos
|
| 10 | Tosto, Giuseppe | Hombre |
Vagelos College of Physicians and Surgeons - Estados Unidos
Gertrude H. Sergievsky Center - Estados Unidos |
| 11 | Mayeux, Richard | Hombre |
Vagelos College of Physicians and Surgeons - Estados Unidos
Gertrude H. Sergievsky Center - Estados Unidos Pontificia Universidad Católica de Chile - Chile |
| 12 | Holtzman, David M. | Hombre |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| 13 | Fagan, Anne M. | Mujer |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| 14 | Morris, J. C. | Hombre |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| 15 | Bateman, Randall J. | Hombre |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| 16 | Goate, Alison M. | Mujer |
Icahn School of Medicine at Mount Sinai - Estados Unidos
|
| 17 | Harari, Oscar | Hombre |
Washington University School of Medicine in St. Louis - Estados Unidos
|
| Fuente |
|---|
| National Institutes of Health |
| NIH Roadmap for Medical Research |
| Medical Research Council |
| Canadian Institutes of Health Research |
| Alzheimer's Association |
| Bristol-Myers Squibb |
| National Cancer Institute |
| Servier |
| Eisai |
| Foundation for the National Institutes of Health |
| National Institute on Aging |
| AbbVie |
| U.S. Department of Defense |
| Pfizer |
| Merck |
| American Federation for Aging Research |
| Eli Lilly and Company |
| Genentech |
| F. Hoffmann-La Roche |
| National Center for Research Resources |
| GE Healthcare |
| Biogen |
| National Institute of Biomedical Imaging and Bioengineering |
| Euroimmun |
| Lundbeckfonden |
| Washington University School of Medicine in St. Louis |
| Takeda Pharmaceutical Company |
| Novartis Pharmaceuticals Corporation |
| Siteman Cancer Center |
| Alzheimer's Disease Research Foundation |
| Lumosity |
| Piramal Imaging |
| Neurotrack Technologies |
| Cogstate |
| Elan Pharmaceuticals, Inc. |
| IXICO Ltd. |
| CereSpir, Inc. |
| NeuroRx Research |
| Transition Therapeutics |
| Alzheimer's Drug Discovery Foundation |
| Janssen Alzheimer Immunotherapy Research & Development, LLC. |
| Araclon Biotech |
| NCI Cancer Center Support |
| DOD ADNI |
| Deutsches Zentrum für Neurodegenerative Erkrankungen |
| DIAN-TU Pharma Consortium |
| ADNI clinical sites in Canada |
| BioClinica |
| ICTS/CTSA |
| Dominantly Inherited Alzheimer Network |
| Johnson & Johnson Pharmaceutical Research & Development LLC. |
| Fujirebio US |
| NIHR Queen Square Dementia Biomedical Research Unit |
| MRC Dementias Platform UK |
| Meso Scale Diagnostics, LLC. |
| Alzheimer's Disease Neuroimaging Initiative |
| Hope Center for Neurological Disorders |
| German Center for Neurodegenerative Diseases |
| Institute of Clinical and Translational Sciences |
| Georgia Clinical and Translational Science Alliance |
| BrightFocus Foundation Alzheimer's Disease Research |
| Alvin J. Siteman Cancer Center |
| DIAN-TU |
| Agradecimiento |
|---|
| Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense, award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. |